Gefitinib administered as first-line in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (IFCT): Predictive biomarkers of efficacy and survival


Intergroupe Francophone de Cancérologie Thoracique (IFCT) • Paris • France

**ABSTRACT**

**OBJECTIVES**

Central pathological review of tumors included in the IFCT0401 clinical trial for central pathological review and molecular analysis in attempt to identify biological predictive markers associated with DC and PFS on gefitinib or OS on gefitinib.

**RESULTS**

Tissue specimens were collected from 65 of the 88 eligible participants whom 14 were from surgical resection and 31 from bronchoscopic or transbronchial biopsy.

**METHODS**

Biomarkers tested were:
- Tissue samples were collected from 65/88 eligible participants, 25 (45%) were ADC alone, 23 (43%) were ADC-BAC, 9 (16%) were pure BAC and 8% others.
- Tumor samples were classified as BAC variants or ADC of other types and as non-mucinous or mucinous/mixed.
- Tumor samples were classified as BAC variants or ADC of other types and as non-mucinous or mucinous/mixed.

**CONCLUSIONS**

Gefitinib (250 mg/dy) was clinically active in previously untreated non-resectable ADC-BAC. Non-smoking, fewer pulmonary symptoms, BAC features, and non-mucinous subtype were predictive factors of efficacy (DCR or PFS).

**Abbreviations**

ADC-BAC, adenocarcinoma with bronchioloalveolar carcinoma features; BAC, bronchioloalveolar carcinoma; CI, confidence interval; CR, clinical remission; DCR, disease control rate; DC, disease control; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization; GEML, gefitinib; HR, hazard ratio; IFCT0401, Intergroupe Francophone de Cancérologie Thoracique 0401; IHC, immunohistochemistry; ISH, in situ hybridization; OS, overall survival; NSCLC, non-small-cell lung cancer; OR, odds ratio; OS, overall survival; PFS, progression-free survival; PFS, progression-free survival; PFS, progression-free survival; PS, performance status; RAS, rat sarcoma; ROC, receiver operating characteristic; RMS, rhabdomyosarcoma; ROS, receptor tyrosine kinase; RR, relative risk; SD, stable disease; TTF1, thyroid transcription factor-1; TNM, tumor-node-metastasis; TS, tumor size; TTF1, thyroid transcription factor-1; VEGF, vascular endothelial growth factor; WHO, World Health Organization.